Hanyang Med Rev.  2017 May;37(1):2-9. 10.7599/hmr.2017.37.1.2.

The first-line regimens of Helicobacter pylori eradication in Korea

• Park CH

• KMID: 2384001
• DOI: http://doi.org/10.7599/hmr.2017.37.1.2

Abstract

Approximately half of the world's population is infected by Helicobacter pylori, which causes various gastrointestinal diseases including gastritis, peptic ulcer, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. The conventional triple therapy, that consists of proton pump inhibitor (PPI), amoxicillin, and clarithromycin, is widely used in Korea because of high resistance rates of H. pylori against metronidazole. Recently, however, clarithromycin-resistance rates have also increased and the eradication rate of conventional triple therapy has been unacceptable. In order to increase the eradication rate of H. pylori, various regimens have been suggested. Understanding H. pylori eradication regimens will help select drugs in the management of H. pylori infection.

Keyword

Helicobacter pylori; Proton pump inhibitor; Antibiotics; Eradication

MeSH Terms

Amoxicillin
Anti-Bacterial Agents
Clarithromycin
Gastritis
Gastrointestinal Diseases
Helicobacter pylori*
Helicobacter*
Korea*
Lymphoma, B-Cell, Marginal Zone
Metronidazole
Peptic Ulcer
Proton Pumps
Stomach Neoplasms
Amoxicillin
Anti-Bacterial Agents
Clarithromycin
Metronidazole
Proton Pumps

Reference

1. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011; 20:299–304.

2. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med. 2010; 362:1597–1604.

3. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13:607–615.

4. Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014; 29:1371–1386.

5. Lee DH, Park HJ, Song SY, Lee SJ, Choi W, Lee YC, et al. Evaluation of therapeutic regimens for the treatment of Helicobacter pylori infection. Yonsei Med J. 1996; 37:270–277.

6. Chung JW, Ha M, Yun S, Kim JH, Lee JJ, Kim YJ, et al. Meta-analysis: Sequential therapy is superior to conventional therapy for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2013; 62:267–271.

7. Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. [Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea]. Korean J Gastroenterol. 2009; 54:269–278.

8. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007; 102:1808–1825.

9. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009; 24:1587–1600.

10. Shin WG, Lee SW, Baik GH, Huh KC, Chung J, Jung WT, et al. Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey. Helicobacter. 2016; 21:266–278.

11. Gong EJ, Yun SC, Jung HY, Lim H, Choi KS, Ahn JY, et al. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change? J Korean Med Sci. 2014; 29:704–713.

12. Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013; 18:206–214.

13. Heo J, Jeon SW, Jung JT, Kwon JG, Lee DW, Kim HS, et al. Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial. J Gastroenterol Hepatol. 2015; 30:1361–1366.

14. Marcus EA, Inatomi N, Nagami GT, Sachs G, Scott DR. The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. Aliment Pharmacol Ther. 2012; 36:972–979.

15. Sheu BS, Kao AW, Cheng HC, Hunag SF, Chen TW, Lu CC, et al. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther. 2005; 21:283–288.

16. Choi HS, Park DI, Hwang SJ, Park JS, Kim HJ, Cho YK, et al. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter. 2007; 12:638–642.

17. Shin JM, Sachs G. Long lasting inhibitors of the gastric H,K-ATPase. Expert Rev Clin Pharmacol. 2009; 2:461–468.

18. Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010; 335:231–238.

19. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016; 65:1439–1446.

20. Matsumoto H, Shiotani A, Katsumata R, Fujita M, Nakato R, Murao T, et al. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Dig Dis Sci. 2016; 61:3215–3220.

21. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007; 12:275–278.

22. Graham DY. Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues. Gut. 2016.

23. Kim JM. [Antibiotic resistance of Helicobacter pylori isolated from Korean patients]. Korean J Gastroenterol. 2006; 47:337–349.

24. Li BZ, Threapleton DE, Wang JY, Xu JM, Yuan JQ, Zhang C, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015; 351:h4052.

25. Kim BG, Lee DH, Ye BD, Lee KH, Kim BW, Kim SG, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter. 2007; 12:31–35.

26. Choi HS, Chun HJ, Park SH, Keum B, Seo YS, Kim YS, et al. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol. 2012; 18:2377–2382.

27. Park SK, Park DI, Choi JS, Kang MS, Park JH, Kim HJ, et al. The effect of probiotics on Helicobacter pylori eradication. Hepatogastroenterology. 2007; 54:2032–2036.

28. Kim MN, Kim N, Lee SH, Park YS, Hwang JH, Kim JW, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter. 2008; 13:261–268.

29. Kim HW, Kim GH, Cheong JY, Yang US, Park SK, Song CS, et al. H pylori eradication: a randomized prospective study of triple therapy with or without ecabet sodium. World J Gastroenterol. 2008; 14:908–912.

30. Song MJ, Park DI, Park JH, Kim HJ, Cho YK, Sohn CI, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter. 2010; 15:206–213.

31. Seo JY, Kim MJ, Ko KH, Kim DH, Lim DS, Chon HR. Efficacy of Ecabet Sodium for Helicobacter pylori Eradication, Combined with Lansoprazole-Based Triple Regimen: A Prospective Study. Korean J Med. 2011; 80:546–552.

32. Zullo A, Rinaldi V, Winn S, Meddi P, Lionetti R, Hassan C, et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2000; 14:715–718.

33. Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010; 44:313–325.

34. De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med. 2006; 144:94–100.

35. Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents. 2002; 19:67–70.

36. Choi WH, Park DI, Oh SJ, Baek YH, Hong CH, Hong EJ, et al. [Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea]. Korean J Gastroenterol. 2008; 51:280–284.

37. Kim YS, Kim SJ, Yoon JH, Suk KT, Kim JB, Kim DJ, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther. 2011; 34:1098–1105.

38. Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, et al. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naive patients. Aliment Pharmacol Ther. 2012; 35:56–65.

39. Oh HS, Lee DH, Seo JY, Cho YR, Kim N, Jeoung SH, et al. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J Gastroenterol Hepatol. 2012; 27:504–509.

40. Kim JS, Kim BW, Hong SJ, Kim JI, Shim KN, Kim JH, et al. Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial. Gut Liver. 2016; 10:556–561.

41. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther. 2011; 34:604–617.

42. Lim JH, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, et al. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter. 2013; 18:180–186.

43. Chung JW, Han JP, Kim KO, Kim SY, Hong SJ, Kim TH, et al. Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: A multicenter, prospective study. Dig Liver Dis. 2016; 48:888–892.

44. Park SM, Kim JS, Kim BW, Ji JS, Choi H. A randomised clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. J Gastroenterol Hepatol. 2017; 32:589–594.

45. Oh DH, Lee DH, Kang KK, Park YS, Shin CM, Kim N, et al. Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. J Gastroenterol Hepatol. 2014; 29:1171–1176.

46. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006; 23:35–44.

47. Peedikayil MC, Alsohaibani FI, Alkhenizan AH. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. PLoS One. 2014; 9:e85620.

48. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006; 101:488–496.

49. Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut. 2010; 59:1465–1470.

50. Zullo A, De Francesco V, Hassan C, Ridola L, Repici A, Bruzzese V, et al. Modified sequential therapy regimens for Helicobacter pylori eradication: a systematic review. Dig Liver Dis. 2013; 45:18–22.

51. Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, et al. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. World J Gastroenterol. 2015; 21:5032–5038.

52. Hwang JJ, Lee DH, Yoon H, Shin CM, Park YS, Kim N. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. World J Gastroenterol. 2015; 21:10234–10241.

53. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim Y, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA. 2005; 293:2756–2761.

54. Lee K, Han MK, Choi HR, Choi C, Oh Y, Lee SD, et al. Annual incidence of latent tuberculosis infection among newly employed nurses at a tertiary care university hospital. Infect Control Hosp Epidemiol. 2009; 30:1218–1222.

55. Chung JW, Lee JH, Jung HY, Yun SC, Oh TH, Choi KD, et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter. 2011; 16:289–294.

56. Lee BH, Kim N, Hwang TJ, Lee SH, Park YS, Hwang J, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter. 2010; 15:38–45.

57. Yoon JH, Baik GH, Kim YS, Suk KT, Shin WG, Kim KO, et al. Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication. Gut Liver. 2012; 6:434–439.

58. Jang HJ, Choi MH, Kim YS, Seo YA, Baik KH, Baik IH, et al. [Effectiveness of triple therapy and quadruple therapy for Helicobacter pylori eradication]. Korean J Gastroenterol. 2005; 46:368–372.

59. Lee JY, Kim N, Park KS, Kim HJ, Park SM, Baik GH, et al. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial. BMC Gastroenterol. 2016; 16:79.